REGN 8-K Current Reports

Earnings & ResultsMaterial AgreementsOther Events

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 30, 2026)

Regeneron Pharmaceuticals, Inc. reported strong third-quarter 2026 financial and operating results, demonstrating robust growth across its key product lines and pipeline advancements. Total revenues surged by 36% year-over-year to $5.1 billion, driven by significant increases in Dupixent, EYLEA HD, and Libtayo sales. This top-line growth translated into substantial bottom-line improvements, with GAAP EPS rising 35% to $18.45 and non-GAAP EPS jumping 70% to $20.07. The company also highlighted progress in its pipeline, including the FDA approval of Pasatru™ (garetosmab) for fibrodysplasia ossificans progressiva (FOP) and positive developments for Libtayo's dosing schedule and indications. Furthermore, Regeneron expanded its collaboration with Sanofi, securing a $1.0 billion upfront payment and potential for additional milestones, signaling confidence in future long-acting immunology antibody developments. These results position Regeneron for a strong year and underscore the continued commercial success and pipeline productivity of the company.

Oct 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Material Agreement (Oct 6, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing a significant amendment to its existing License and Collaboration Agreement (LCA) with Sanofi. This Sixth Amendment focuses on the co-development and co-commercialization of four novel, Regeneron-invented long-acting antibodies targeting key inflammatory pathways (IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13). This strategic move significantly expands Regeneron's pipeline in high-potential therapeutic areas. The financial implications for Regeneron are substantial. Sanofi will provide an upfront payment of $1.0 billion, with the potential for an additional $7.0 billion in milestone payments tied to development, regulatory, and commercial success. This partnership also includes a balanced approach to cost-sharing for development, with Regeneron acting as the lead development and regulatory party in the U.S. Additionally, the report discloses an expected $22 million pre-tax acquired in-process R&D charge for Q3 2026, impacting EPS by approximately $0.18. The settlement of a prior lawsuit regarding Dupixent commercialization information is also a notable event.

Oct 6, 2026 8-K

Leadership ChangesExhibits & Filings

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Sep 30, 2026)

Regeneron (REGN) filed an 8-K on September 30, 2026 disclosing two governance and compensation actions. First, effective September 24, 2026, the Compensation Committee, with approval from independent directors, granted co-founders Leonard Schleifer (CEO) and George Yancopoulos (CSO) a one-time, 100% performance-based award of performance share units (2026 PSUs) under the 2014 Long-Term Incentive Plan. The awards replace annual long-term incentive grants for both executives through 2036, run over a 10-year performance period (2026–2035), and carry a mandatory holding period into February 2036. Payouts depend on new product filings and approvals (smaller earnout) and new product revenues (the largest earnout), with a relative TSR modifier of up to ±20% against the NASDAQ Biotechnology Index. Hard caps are 2.7 million PSUs for the CEO and 2.9 million for the CSO, and the maximum earnout requires roughly $30 billion in annual new-product revenue, about double Regeneron's 2025 total revenue. Second, the Company formed a New Subsidiary to explore a potential non-core business. Both executives received partially vesting equity stakes in it. The company describes the entity as nominal in value, without significant assets, not yet operating, and possibly never pursuing the opportunity. Its financial impact appears immaterial at this stage. For investors, the key points are the alignment of the co-founders' pay with long-term pipeline and commercial delivery, and the design choices shaped by shareholder engagement, including the heavier weighting toward revenue and the succession planning requirement. Retention risk is reduced because forfeiture applies on voluntary departure. Dilution and expense are a consideration, though the filing does not quantify the grant-date fair value or the dilutive effect of the awards.

Sep 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 30, 2026)

Regeneron reported second quarter 2026 results on July 30, 2026, with total revenues up 17% year over year to $4.29 billion and non-GAAP EPS up 11% to $14.29, marking a second consecutive quarter of double-digit growth on both top and bottom lines. Growth was driven largely by the Sanofi collaboration, where Regeneron's share of antibody profits rose to $2.03 billion from $1.28 billion on higher Dupixent sales (global Dupixent sales up 38% to $6.0 billion). U.S. EYLEA HD sales grew 52% to $596 million and Libtayo global sales rose 30% to $489 million, while legacy U.S. EYLEA fell 45% as patients transition to EYLEA HD. GAAP EPS was $12.23, reflecting a $1.02 per share hit from acquired IPR&D charges, and GAAP EPS declined 5% year over year. Management highlighted that the Sanofi Development Balance was fully repaid by the end of the second quarter, which removes a reduction to Sanofi collaboration revenue starting in the third quarter and should meaningfully lift collaboration profits. Gross margin on net product sales was pressured by a temporary interruption of bulk manufacturing at the Limerick, Ireland facility, though production has returned to normal levels. The company raised the midpoint of several 2026 non-GAAP guidance items, including non-GAAP gross margin (now 84%-85%) and non-GAAP R&D, while lowering capital expenditure guidance to $1.03-$1.10 billion. Capital returns remain significant, with $2.0 billion of share repurchases in the first half and a $0.94 quarterly dividend declared. Pipeline news was mixed. The Phase 3 fianlimab plus cemiplimab melanoma trial missed its primary PFS endpoint, while cemdisiran was accepted for review in gMG by both the FDA (priority review, target action date November 2026) and the EMA. Investors should also note that the balance sheet shows cash and marketable securities declining to $17.8 billion from $18.9 billion, and the company's own results include forward-looking caveats tied to Sanofi and Bayer collaboration dependence, EYLEA competition, and pending DOJ-related litigation.

Jul 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 6, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 6, 2026, providing a preliminary update on its expected financial results for the second quarter of 2026. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $127 million. This charge is primarily related to up-front and opt-in payments made under various collaboration and licensing agreements. The estimated impact of this acquired IPR&D charge is a reduction of approximately $1.00 per diluted share on both Generally Accepted Accounting Principles (GAAP) and non-GAAP net income for the second quarter. Regeneron cautions that these are preliminary estimates and subject to change as financial closing procedures are completed, and actual results may differ. Investors should note that IPR&D charges are inherently unpredictable due to the uncertain nature of future collaborations and development milestones.

Jul 6, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Shareholder Vote Results (Jun 17, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 17, 2026, detailing the results of its 2026 Annual Meeting of Shareholders held on June 12, 2026. The report confirms the election of Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, shareholders provided advisory approval for executive compensation. Key outcomes include the successful election of all nominated directors, indicating strong shareholder confidence in the current board's leadership. The ratification of the auditor received substantial support, reinforcing the company's commitment to financial transparency and robust auditing practices. The advisory vote on executive compensation also passed with a significant majority, suggesting shareholder alignment with the company's compensation philosophy for its named executive officers.

Jun 17, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 29, 2026)

Regeneron reported first quarter 2026 results that showed strong top-line and earnings growth, with total revenues up 19% to $3.605 billion and non-GAAP diluted EPS up 15% to $9.47. GAAP diluted EPS was $6.75, down 7% year over year, reflecting $0.82 of acquired IPR&D charges and $0.80 of IPR&D impact on non-GAAP results, plus a temporary manufacturing interruption at the Limerick, Ireland facility. Growth was driven largely by Sanofi collaboration revenue (up 36%, with Dupixent global sales up 33% to $4.9 billion), while U.S. EYLEA HD sales rose 52% to $468 million, though combined EYLEA HD and EYLEA U.S. sales fell 10% to $941 million as patients transition to EYLEA HD and competition intensifies. Key regulatory and pipeline events included FDA approvals for EYLEA HD extended dosing up to every 20 weeks, Dupixent in pediatric CSU and allergic fungal rhinosinusitis, and Otarmeni, a gene therapy for OTOF-related hearing loss that Regeneron will provide free in the U.S. A notable overhang is the EYLEA HD pre-filled syringe, where the FDA has not yet acted on a PDUFA date for a second filler, with a decision expected in Q2 2026. Phase 3 fianlimab melanoma data are due in Q2 2026, while the NSCLC program was dropped from Phase 3 advancement. Capital allocation remained shareholder-friendly, with $803 million of buybacks in the quarter, a new $3.0 billion repurchase authorization, and a $0.94 quarterly dividend. Management trimmed 2026 capex guidance to $1.1–$1.2 billion and lowered its GAAP gross margin guidance to 77%–78% due to the Limerick disruption, while leaving most other guidance unchanged. The company also announced an April 2026 agreement with the U.S. government on Most-Favored-Nation drug pricing, with a three-year tariff relief provision in return.

Apr 29, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 8, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose anticipated financial results for the first quarter of 2026. The company expects to record an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis. This charge is primarily associated with equity securities purchased and payments made under collaboration and licensing agreements. The most significant impact for investors is the expected negative effect of this IPR&D charge on both GAAP and non-GAAP net income per diluted share, estimated at $0.81 for the first quarter of 2026. It's important to note that these are preliminary estimates, subject to finalization of financial closing procedures, and actual results could differ. The company also highlighted that acquired IPR&D charges are inherently unpredictable and not typically forecasted.

Apr 8, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 30, 2026)

Regeneron reported fourth quarter and full year 2025 results on January 30, 2026, with modest top-line growth driven by strong Dupixent economics offset by continued erosion of EYLEA. Q4 2025 total revenues rose 3% to $3.88 billion, and full year revenues rose 1% to $14.34 billion. GAAP EPS was $7.86 in Q4 (down 2%) and $41.48 for the full year (up 8%), while non-GAAP EPS was $11.44 in Q4 (down 5%) and $44.31 for the year (down 3%). Full-year GAAP net income of $4.5 billion was lifted by $946 million of securities gains, and non-GAAP net income declined 8% to $4.9 billion. The key story is the divergence between partner-driven and U.S. franchise performance. Dupixent global net sales (recorded by Sanofi) grew 26% for the year to $17.8 billion, and Regeneron's share of antibody profits from Sanofi rose to $5.2 billion, which is now the company's main revenue engine. In contrast, total U.S. EYLEA HD and EYLEA net sales fell 27% to $4.4 billion as legacy EYLEA lost volume to competition and compounded bevacizumab, partly offset by 36% growth in EYLEA HD to $1.6 billion. Non-GAAP gross margin on net product sales compressed to 85% from 88%, and R&D spending rose 13% on a non-GAAP basis. Looking ahead, management guided 2026 non-GAAP R&D to $5.9–6.1 billion, non-GAAP SG&A to $2.5–2.65 billion, and capital expenditures to $1.1–1.3 billion, and it excludes unannounced business development deals. The company declared a $0.94 per share dividend and had $1.5 billion remaining under its buyback authorization, after repurchasing $3.5 billion of stock in 2025. Near-term catalysts include an FDA decision on the EYLEA HD pre-filled syringe and DB-OTO in the first half of 2026, an AFRS sBLA decision in February 2026, and Phase 3 readouts for fianlimab and cemdisiran in 2026.

Jan 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 12, 2026)

Regeneron (REGN) filed this 8-K on January 12, 2026, furnishing a J.P. Morgan Healthcare Conference presentation by CEO Leonard Schleifer and CSO George Yancopoulos. The filing is primarily a corporate update with preliminary, unaudited Q4 and full-year 2025 information that remains subject to closing procedures. Two discrete items were disclosed: an acquired in-process R&D (IPR&D) charge of approximately $19 million pre-tax in Q4 2025, which reduces both GAAP and non-GAAP diluted EPS by about $0.14, and an approximately $60 million matching contribution to the Good Days Retinal Vascular and Neovascular Disease Fund, recorded in SG&A. The presentation shows strong commercial momentum. Dupixent global net sales were $736M in Q4 2025 per the slide, and EYLEA HD physician demand grew 10% quarter over quarter. Management noted that Q4 EYLEA HD and EYLEA U.S. net sales were each favorably impacted by roughly $30 million from higher wholesaler inventory, so underlying demand is somewhat lower than reported. Management also reported capital returns of about $3.8 billion in 2025 (roughly $3.4 billion in buybacks and $0.4 billion in dividends), with a quarterly dividend of $0.88 per share initiated in 2025 and about $1.5 billion remaining under the repurchase authorization. Projected 2026 non-GAAP R&D spend is above $7 billion, and GAAP R&D is estimated at about $6.5 billion. For investors, the filing's near-term catalysts are concentrated in 1H 2026: pivotal fianlimab plus cemiplimab data in first-line metastatic melanoma, a DB-OTO FDA decision, an EYLEA HD pre-filled syringe decision in 2Q 2026, and several Factor XI and obesity Phase 3 starts. Formal 2026 financial guidance was deferred to the Q4 2025 earnings release. The filing also flags pending DOJ-related litigation and EYLEA patent litigation as risk factors.

Jan 12, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 28, 2025)

Regeneron reported third quarter 2025 results with total revenues up 1% year-over-year to $3.75 billion, but the top line masks a sharp shift in mix. U.S. EYLEA sales fell 41% to $681 million as patients moved to EYLEA HD and faced biosimilar and compounded bevacizumab pressure, while Dupixent (recorded by Sanofi) grew 27% to $4.86 billion globally, lifting Regeneron's share of collaboration profits to $1.46 billion. GAAP EPS was $13.62 versus $11.54 a year ago, helped by $578 million of securities gains, while non-GAAP EPS fell 5% to $11.83 and was reduced by a $0.68 acquired IPR&D charge. Non-GAAP net income declined 12% to $1.29 billion, so the GAAP beat is largely non-operating in nature. Pipeline and regulatory news was mixed. Libtayo received FDA approval as the first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma, and positive Phase 3 data were reported in generalized myasthenia gravis, FOP, and cat and birch allergies. Management also disclosed a setback: the FDA issued a Complete Response Letter for the EYLEA HD pre-filled syringe sBLA, citing unresolved inspection findings at contract filler Catalent, and the company plans to resubmit with a new filler by January 2026. Other near-term catalysts include an EYLEA HD every-four-week dosing and RVO decision expected in late November 2025 and a DB-OTO filing planned for Q4 2025 with a National Priority Voucher. Financially, the company returned over $3 billion to shareholders in the first nine months through buybacks and dividends, with $2.156 billion remaining authorization. Management lowered full-year 2025 non-GAAP R&D and SG&A guidance and raised the GAAP effective tax rate to about 14% due to a $45 million charge from the One Big Beautiful Bill Act. Free cash flow for the nine months was $3.16 billion, up from $2.60 billion. Investors should weigh the EYLEA franchise erosion and manufacturing-related regulatory risk against Dupixent-driven collaboration income and a strong balance sheet.

Oct 28, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 6, 2025)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing an expected acquired in-process research and development (IPR&D) charge of approximately $83 million on a pre-tax basis for the third quarter of 2025. This charge is primarily linked to an $80 million upfront payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The company anticipates this IPR&D charge will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.68 for the quarter.

Oct 6, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Aug 1, 2025)

Regeneron reported second quarter 2025 results on August 1, 2025, with total revenues up 4% to $3.68 billion and GAAP EPS up 3% to $12.81 (non-GAAP EPS up 12% to $12.89). Growth was driven by Dupixent, where Regeneron's share of antibody profits rose to $1.28 billion, and by U.S. EYLEA HD sales, which grew 29% to $393 million. These gains were offset by a 39% decline in U.S. EYLEA sales to $754 million, reflecting competitive pressure, share loss to compounded bevacizumab, and patient transition to EYLEA HD. Total EYLEA HD and EYLEA U.S. sales fell 25% to $1.15 billion. The quarter also brought several regulatory and pipeline developments. The FDA approved Lynozyfic for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and CSU, and accepted a Libtayo adjuvant CSCC sBLA for priority review with an October 2025 target action date. Offsetting these, the FDA issued a Complete Response Letter for odronextamab on July 30, and the company expects delays for pending EYLEA HD FDA applications with August 2025 PDUFA dates. Both issues trace to an FDA inspection at Catalent Indiana, a filler now owned by Novo Nordisk. In addition, the Phase 3 AERIFY-2 trial for itepekimab in COPD missed its primary endpoint, while AERIFY-1 met it. Management raised its 2025 GAAP R&D and GAAP SG&A guidance ranges and narrowed or lowered several other items, while raising the GAAP effective tax rate guidance to 11%-13%. The company returned over $2.3 billion to shareholders in the quarter through buybacks and dividends, with $2.81 billion remaining under its repurchase authorization. Second quarter GAAP net income declined 3% to $1.39 billion, helped by $250 million of unrealized equity-security gains that flatter results relative to operating performance.

Aug 1, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Shareholder Vote Results (Jun 18, 2025)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing the outcomes of its 2025 Annual Meeting of Shareholders held on June 13, 2025. The key takeaways for investors revolve around significant governance changes and shareholder confidence in the company's direction and leadership. Shareholders overwhelmingly re-elected all Class I directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025, indicating strong support for the current board and financial oversight. Furthermore, investors approved an advisory vote on executive compensation, demonstrating confidence in the company's compensation practices. A notable governance shift occurred with the approval to declassify the board of directors, moving towards a more standard annual election of all board members. However, proposals to eliminate certain supermajority vote requirements for specific charter amendments did not pass, suggesting a desire among some shareholders for existing protections or a cautious approach to altering these provisions.

Jun 18, 2025 8-K

Earnings & ResultsOther EventsExhibits & Filings

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 29, 2025)

Regeneron reported first quarter 2025 results on April 29, 2025, with total revenues of $3.03 billion (down 4% year over year) and GAAP diluted EPS of $7.27 (up 16%), while non-GAAP diluted EPS fell 14% to $8.22. The top-line decline was driven by EYLEA, where combined EYLEA HD and EYLEA U.S. net sales fell 26% to $1.04 billion as legacy EYLEA lost volume to biosimilars, compounded bevacizumab, and the transition to EYLEA HD. EYLEA HD U.S. sales grew 54% to $307 million, a bright spot, but not enough to offset the legacy decline. Partly offsetting this, Sanofi collaboration revenue rose 30% to $1.18 billion on higher Dupixent sales, which grew 19% globally to $3.67 billion. The quarter also brought mixed regulatory news. Dupixent was approved in the U.S. for chronic spontaneous urticaria, and EYLEA HD received a Complete Response Letter for its pre-filled syringe, tied to a third-party component supplier, and a separate CRL limiting extended dosing intervals to no longer than every 16 weeks. Management kept full-year 2025 R&D and SG&A guidance unchanged, lowered GAAP and non-GAAP gross margin guidance, and narrowed capital expenditure guidance. Capital returns continued with $1.05 billion in Q1 buybacks, $3.87 billion of remaining authorization, and a first-time $0.88 per share dividend declared for June payment. For investors, the key issues are whether EYLEA HD growth can offset legacy erosion, the timing of the EYLEA HD syringe and dosing resubmissions, gross margin pressure from inventory write-offs, and the cadence of pipeline readouts expected later in 2025.

Apr 29, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Feb 4, 2025)

Regeneron reported strong fourth quarter and full year 2024 results on February 4, 2025, with total revenues rising 10% to $3.79 billion in Q4 and 8% to $14.20 billion for the full year. Growth was driven largely by Dupixent, whose global net sales (recorded by Sanofi) rose 22% for the year to $14.15 billion, lifting Regeneron's share of antibody profits from Sanofi collaboration revenue to $3.92 billion. EYLEA HD continued its launch trajectory, contributing $1.20 billion in full-year U.S. sales, while combined U.S. EYLEA HD and EYLEA sales grew only 1% as legacy EYLEA declined 17% for the year and net selling prices fell. Libtayo grew 40% to $1.22 billion. GAAP diluted EPS was $38.34 for the year (up 10%), and non-GAAP EPS was $45.62 (up 4%); Q4 GAAP EPS of $8.06 was down 21%, weighed by $213 million of unrealized losses on equity securities. Capital allocation was the headline announcement. Regeneron initiated its first quarterly cash dividend of $0.88 per share, payable March 20, 2025 to holders of record on February 20, 2025, and authorized an additional $3.0 billion share repurchase program, bringing total repurchase capacity to roughly $4.5 billion. The company repurchased $2.6 billion of stock in 2024, including $976 million in Q4, and reported free cash flow of $3.66 billion for the year. Management frames the dividend as an ongoing quarterly commitment subject to board discretion and market conditions. For 2025, the company issued detailed guidance, including non-GAAP R&D of $5.00–$5.20 billion, non-GAAP SG&A of $2.55–$2.70 billion, a non-GAAP gross margin on net product sales of 87%–88%, and a non-GAAP effective tax rate of 11%–13%. The pipeline calendar features several near-term catalysts, including an sBLA for EYLEA HD in retinal vein occlusion, a Dupixent CSU action date of April 18, 2025, an EYLEA HD two-year data action date of April 20, 2025, and a linvoseltamab FDA decision expected mid-2025.

Feb 4, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 13, 2025)

Regeneron's January 13, 2025 Form 8-K, furnished under Items 2.02 and 7.01, pairs preliminary (unaudited) fourth-quarter and full-year 2024 results with the company's J.P. Morgan Healthcare Conference presentation. The headline numbers are about $6 billion in aggregate U.S. net sales for EYLEA HD and EYLEA in 2024, up 1% year over year, and Libtayo surpassing $1 billion in 2024 annual net sales. The filing also discloses a fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, which reduces GAAP and non-GAAP diluted EPS by about $0.11. Results are not finalized and remain subject to closing procedures. The pipeline and regulatory updates are the other focus. Libtayo delivered the first statistically significant disease-free survival benefit in high-risk adjuvant cutaneous squamous cell carcinoma (68% risk reduction, HR 0.32), with an FDA submission planned for the first half of 2025. The linvoseltamab BLA was resubmitted with launch expected in mid-2025, and the odronextamab FL BLA resubmission is planned for Q1 2025. Dupixent is now used by over one million patients globally, with a COPD launch underway and a CSU FDA decision due April 18, 2025. Key investor considerations include the EYLEA HD pre-filled syringe launch (mid-2025), the April 20, 2025 PDUFA date for extended EYLEA HD dosing, and 2025 Phase 3 readouts for itepekimab in COPD and fianlimab plus Libtayo in melanoma. The filing also includes standard forward-looking statement cautions and notes that EYLEA HD and EYLEA results were partly boosted by about $85 million of wholesaler inventory build for EYLEA.

Jan 13, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 31, 2024)

Regeneron reported third quarter 2024 results on October 31, 2024, with total revenues up 11% year over year to $3.72 billion and GAAP diluted EPS up 30% to $11.54 (non-GAAP diluted EPS up 8% to $12.46). Growth was led by Dupixent, whose global net sales recorded by Sanofi rose 23% to $3.82 billion, and by Regeneron's share of antibody profits from Sanofi collaboration, which rose to $1.09 billion from $863 million. Net income was $1.34 billion, helped by $135 million of unrealized gains on equity securities and $187 million of interest income, which flatter GAAP earnings relative to operating income of $1.18 billion. The retinal franchise showed a mixed picture. Combined U.S. EYLEA HD and EYLEA net sales grew only 3% to $1.54 billion, with EYLEA HD contributing $392 million in its first full post-launch comparison period. Standard EYLEA sales fell 21% as lower net selling prices and transition to EYLEA HD eroded the legacy product, and about $40 million of EYLEA HD sales came from higher wholesaler inventory rather than end demand. Libtayo grew 24% to $289 million globally. Management also updated 2024 guidance: GAAP R&D was narrowed, non-GAAP SG&A was lowered at the top end, capital expenditures were cut to $700–740 million, and COCM was raised to $860–900 million. The company repurchased $738 million of stock in the quarter and had $2.9 billion remaining under its authorization. The pipeline news was mostly positive. Dupixent received its first FDA approval as a biologic for COPD with an eosinophilic phenotype, the Chronic Spontaneous Urticaria (CSU) and bullous pemphigoid (BP) trials met their endpoints, and the CSU sBLA was resubmitted. The main setback was an FDA Complete Response Letter for linvoseltamab in multiple myeloma, which was tied to a third-party fill/finish manufacturer inspection and must be resolved before approval in the U.S. or EU.

Oct 31, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 7, 2024)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on October 7, 2024, providing a preliminary update on its expected financial results for the third quarter of 2024. The company anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $56 million on a pre-tax basis. This charge is a result of development milestone and up-front payments tied to collaboration and licensing agreements. This IPR&D charge is projected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43 for the third quarter. Investors should note that these are preliminary estimates, and the actual results are subject to the company's financial statement closing procedures and could differ. Regeneron emphasizes that acquired IPR&D charges are inherently unpredictable due to the uncertainty in timing and magnitude of such transactions, and therefore are not typically forecasted.

Oct 7, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Aug 1, 2024)

Regeneron reported second quarter 2024 results with total revenue up 12% year over year to $3.55 billion, driven by Dupixent (recorded by Sanofi), which grew 27% to $3.56 billion in global net sales, and by notable growth in EYLEA HD and Libtayo. GAAP diluted EPS rose 46% to $12.41, while non-GAAP diluted EPS rose 13% to $11.56. The quarter's GAAP results were flattered by $393 million of unrealized gains on equity securities, so the non-GAAP figures are the better read on core operating performance. Management also highlighted the first European Commission approval of Dupixent for COPD, with a U.S. FDA decision now expected by September 27, 2024 after a three-month extension. The U.S. EYLEA franchise (EYLEA HD plus EYLEA) grew only 2% to $1.53 billion. EYLEA HD contributed $304 million, which offset a sharp 18% decline in legacy EYLEA sales as patients transitioned to the higher-dose product. Operating expenses rose across the board, with SG&A up 16% on EYLEA HD launch costs and COGS up 34% on start-up costs for the Rensselaer fill/finish facility. Full-year 2024 guidance was narrowed, with GAAP R&D and SG&A ranges adjusted and capital expenditure guidance lowered to $750–$820 million. The company ended the quarter with $17.5 billion in cash and marketable securities and repurchased $601 million of stock, with $3.6 billion still authorized. The filing shows a company with strong growth in its immunology franchise, a growing oncology pipeline, and solid balance sheet flexibility. The key watch items for investors are the timing of Dupixent's FDA COPD decision, the pace of EYLEA HD conversion against the legacy EYLEA decline, and the second-half pipeline readouts management flagged.

Aug 1, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 8, 2024)

Regeneron Pharmaceuticals, Inc. has filed a Current Report on Form 8-K to provide preliminary insights into its second quarter 2024 financial results. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $24 million. This charge, stemming from collaboration and licensing agreements, is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the quarter. While these figures are preliminary and subject to closing procedures, they offer investors an early look at a specific cost impacting the quarter's profitability.

Jul 8, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Shareholder Vote Results (Jun 20, 2024)

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report detailing the outcomes of its 2024 Annual Meeting of Shareholders held on June 14, 2024. The primary focus of this filing is the voting results on several key proposals, including the election of directors, ratification of its independent auditor, advisory vote on executive compensation, and a shareholder proposal regarding simple majority voting. All proposals presented to shareholders, with the exception of one, received strong support, indicating continued confidence from the company's investors in its governance and operational direction. Of particular note, all nominated directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm was overwhelmingly ratified. The advisory vote on executive compensation also passed. However, a shareholder proposal advocating for simple majority voting requirements also received a majority of the votes cast, suggesting a desire among some shareholders for changes in the company's voting structure. Investors should monitor any subsequent actions or responses from the company regarding this approved shareholder proposal.

Jun 20, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (May 2, 2024)

Regeneron reported first quarter 2024 results on May 2, 2024, with total revenues of $3.15 billion, down 1% year over year, but up 7% excluding Ronapreve collaboration revenue that is not expected to recur. The decline was driven mainly by lower U.S. EYLEA sales (down 16% to $1.20 billion), partly offset by the launch of EYLEA HD ($200 million in its first quarter on market). Growth engines were Dupixent (global sales recorded by Sanofi up 24% to $3.08 billion, flowing through Regeneron's profit share in Sanofi collaboration revenue) and Libtayo (global net sales up 45% to $264 million). Profitability declined: GAAP diluted EPS fell 13% to $6.27 and non-GAAP diluted EPS fell 5% to $9.55, reflecting higher R&D (up 13% GAAP) and SG&A (up 15% GAAP) spending to support launches and pipeline advancement, along with unrealized equity investment losses of $196 million. Management highlighted a new $3.0 billion share repurchase authorization in April 2024, on top of $1.2 billion remaining under the prior program, signaling continued capital return alongside investment in innovation. Cash and marketable securities rose to $17.5 billion from $16.2 billion at year-end 2023, and free cash flow was $1.38 billion versus $1.19 billion a year earlier. Full-year 2024 guidance was mixed: GAAP and non-GAAP R&D were raised, GAAP SG&A floor was raised, and capital expenditure guidance was lowered to $780-880 million; the 2seventy bio acquisition costs were incorporated into the R&D outlook. Key pipeline catalysts include the linvoseltamab BLA decision (target action date August 22, 2024) and the odronextamab complete response letters, which cited only trial enrollment status as an approvability issue.

May 2, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Feb 2, 2024)

Regeneron's Q4 and full-year 2023 results, furnished under Item 2.02 via Exhibit 99.1, show a company growing its top line while absorbing heavy R&D and commercial investment. Q4 2023 total revenues rose 1% to $3.43 billion, but excluding Ronapreve (COVID-19 antibody sales recorded by Roche) revenues grew 14%. Full-year revenues increased 8% to $13.12 billion, or 12% excluding Ronapreve. Growth was driven largely by Dupixent, whose global net sales (recorded by Sanofi) rose 33% for the year to $11.59 billion. Regeneron's share of antibody profits from Dupixent flowed through Sanofi collaboration revenue, which increased 33% for the year. Profitability was weaker. GAAP diluted EPS fell 9% to $34.77 for 2023, and non-GAAP EPS fell 3% to $43.79. Q4 GAAP EPS was $10.19, which included a $0.21 hit from acquired IPR&D. U.S. EYLEA franchise sales declined 9% for the year, reflecting lower net price and volume, while the launch of EYLEA HD in August 2023 contributed $166 million. R&D spending rose 24% on a GAAP basis, and SG&A rose 24%. Higher interest income of $496 million and a very low effective tax rate (5.9% GAAP for the year) cushioned the results. Cash and marketable securities reached $16.2 billion, and free cash flow was $3.9 billion. For 2024, management guided to GAAP R&D of $4.82–$5.07 billion, GAAP SG&A of $2.89–$3.09 billion, and a GAAP effective tax rate of 8–10%. The company also announced the CFO's retirement and several pipeline and regulatory milestones, including an odronextamab FDA action date of March 31, 2024. Investors will likely focus on whether Dupixent and EYLEA HD can offset EYLEA erosion and whether rising operating costs translate into earnings growth.

Feb 2, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Jan 31, 2024)

Regeneron Pharmaceuticals, Inc. (REGN) has announced a planned succession in its finance leadership team. Effective February 5, 2024, following the filing of their 2023 Form 10-K, Christopher Fenimore will be appointed as Senior Vice President, Finance and Chief Financial Officer, succeeding the retiring Robert E. Landry. Concurrently, Jason Pitofsky will be promoted to Vice President, Controller. This transition is part of a previously disclosed CFO succession plan. Mr. Fenimore, with extensive experience within Regeneron and prior roles in the biotech and finance sectors, will see his 2024 base salary adjusted to $660,000 and received a significant equity award in December 2023 valued at $5 million. Mr. Pitofsky's appointment to Controller is a promotion from his previous role as VP, Accounting and Financial Reporting, with no immediate changes to his compensation. Investors can view this as a continuation of internal talent development and a structured handover of critical financial oversight.

Jan 31, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 8, 2024)

Regeneron (REGN) used its appearance at the 42nd J.P. Morgan Healthcare Conference on January 8, 2024 to furnish preliminary, unaudited fourth-quarter 2023 U.S. net product sales: approximately $123 million for EYLEA HD (aflibercept 8 mg), its first full quarter after FDA approval for wet AMD, DME and DR, and approximately $1.34 billion for the established EYLEA franchise. Combined U.S. EYLEA family sales were roughly $1.46 billion. The EYLEA HD launch is the central investor focus, as management argues it can become the next-generation standard of care in anti-VEGF therapy, citing early broad uptake, roughly two-thirds of eligible lives with coverage, and a permanent J-Code expected April 1, 2024. The filing also discloses a $30 million pre-tax acquired IPR&D charge in Q4 2023 tied to a payment to extend the Intellia Therapeutics collaboration. The charge is expected to reduce both GAAP and non-GAAP diluted EPS by about $0.21. Regeneron does not forecast such charges because their timing and size are uncertain, so investors should treat the reported figures as preliminary and subject to closing procedures. The accompanying presentation (Exhibit 99.1) is a broad 2024 strategic update covering the Dupixent COPD opportunity and its pending sBLA, Libtayo growth expected to exceed $1 billion in 2024, linvoseltamab and odronextamab regulatory milestones, CD28 costimulatory bispecifics, obesity and genetic medicine programs, and a 2024 milestone calendar. Because the Q4 figures are unaudited and the filing is largely a forward-looking presentation, the near-term catalysts are the EYLEA HD uptake trajectory, the odronextamab and linvoseltamab regulatory decisions, and the Dupixent COPD approval timing.

Jan 8, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Nov 2, 2023)

Regeneron reported third quarter 2023 total revenues of $3.36 billion, up 15% year over year, driven primarily by strong Dupixent performance flowing through the Sanofi collaboration (Sanofi collaboration revenue up 50% to $1.07 billion) and Libtayo growth of 62% on a global basis. GAAP diluted EPS fell to $8.89 from $11.66 (down 24%), but non-GAAP diluted EPS rose 4% to $11.59. The GAAP figure absorbed a $100 million acquired IPR&D charge tied to a development milestone for the ALN-APP program with Alnylam, worth about $0.77 per share, and a $100 million net unrealized loss on equity securities, which contrasted with a $254 million gain a year earlier. Interest income of $134 million partly offset these items. U.S. EYLEA net sales declined 11% to $1.45 billion as competition and lower net selling prices weighed on the franchise. The newly approved EYLEA HD contributed $43 million in its first partial quarter following its August 2023 FDA approval for wet AMD, diabetic macular edema, and diabetic retinopathy. Total net product sales were roughly flat at $1.79 billion. Management also raised the low end of several 2023 guidance ranges, lowering capital expenditure guidance to $660–$700 million and narrowing non-GAAP R&D and SG&A ranges. Regeneron repurchased $507 million of stock in the quarter and retains $1.8 billion of authorization. Pipeline and governance news included FDA priority review for odronextamab (target action date March 31, 2024) and for pediatric Dupixent in eosinophilic esophagitis (target date January 31, 2024), alongside a Complete Response Letter for Dupixent in chronic spontaneous urticaria requiring additional efficacy data. The company also completed the Decibel Therapeutics acquisition for $101 million upfront, announced that CFO Robert Landry will retire in February 2024, and named Christopher Fenimore as his successor.

Nov 2, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 5, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose an expected $100 million pre-tax acquired in-process research and development (IPR&D) charge for the third quarter of 2023. This charge is primarily related to a development milestone payment for the Phase 1 ALN-APP program in early-onset Alzheimer's disease, stemming from Regeneron's collaboration with Alnylam Pharmaceuticals, Inc. This IPR&D charge is anticipated to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.78 for the quarter. While this charge will impact reported earnings, it represents a milestone achievement in the company's research pipeline. Regeneron notes that these IPR&D charges are inherently unpredictable in timing and magnitude and are therefore not typically forecasted.

Oct 5, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Sep 8, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing significant changes within its board of directors and executive leadership. Notably, the company announced the retirement of its Chief Financial Officer, Robert E. Landry, who has served in that capacity since 2013. Mr. Landry plans to retire in February 2024, and the company has appointed Christopher Fenimore, currently Senior Vice President, Controller, as his successor, ensuring a smooth transition in financial leadership. In addition to the CFO transition, Regeneron has elected two new independent directors to its Board: Dr. Kathryn Guarini and Dr. David P. Schenkein. These appointments are intended to fill existing vacancies and strengthen the Board's expertise. The report also discloses the departure of Dr. Marc Tessier-Lavigne as a director due to potential conflicts arising from increased involvement with other companies. These leadership changes, while significant, are presented as strategic moves to ensure continued strong governance and financial oversight at Regeneron.

Sep 8, 2023 8-K/A

Regeneron Pharmaceuticals 8-K/A Report, Shareholder Vote Results (Sep 8, 2023)

This filing is an amendment to a previous 8-K report and serves to clarify Regeneron Pharmaceuticals, Inc.'s decision regarding the frequency of shareholder advisory votes on executive compensation. The company's Board of Directors, accepting the recommendation of its Compensation and Corporate Governance committees, has determined that these advisory votes will continue to be held annually. This decision follows a shareholder vote at the 2023 Annual Meeting of Shareholders held on June 9, 2023, where the option for a one-year frequency received a majority of the votes cast. The amendment, filed on September 7, 2023, with an event date of June 8, 2023, is a procedural update to formally disclose this outcome and the Board's subsequent confirmation.

Sep 8, 2023 8-K

Shareholder MattersCorporate ChangesExhibits & Filings

Regeneron Pharmaceuticals 8-K Report, Financial Results (Aug 3, 2023)

Regeneron (REGN) reported second quarter 2023 results on August 3, 2023, with total revenues up 11% year over year to $3.16 billion and GAAP diluted EPS of $8.50 (up 14%). Non-GAAP diluted EPS was $10.24 (up 5%). Growth was driven by Sanofi collaboration revenue, which rose 39% to $944 million on higher Dupixent profit-sharing, while Dupixent global net sales (recorded by Sanofi) grew 33% to $2.79 billion. Offsetting this, U.S. EYLEA net sales fell 7% to $1.50 billion on lower net selling prices amid increased competition, and operating expenses rose sharply, with GAAP R&D up 37% and SG&A up 37%. The most important near-term item is the FDA Complete Response Letter for aflibercept 8 mg received in June 2023. The CRL was tied solely to inspection observations at third-party filler Catalent, not to clinical efficacy or safety. Regeneron expects to submit the required data by mid-August and anticipates FDA action in the third quarter of 2023. The company also reported two-year PHOTON data in DME, and the PULSAR wet AMD two-year data are still expected in the third quarter. Other items for investors include a discontinued enrollment in the REGN5678 plus full-dose Libtayo prostate cancer cohort after two immune-mediated Grade 5 adverse events, a 2025 readout for itepekimab COPD studies after passing an interim futility analysis, and a favorable Supreme Court ruling ending the Praluent patent dispute. The company raised its 2023 GAAP R&D and SG&A guidance ranges at the low end and lowered capital expenditure guidance. Cash and marketable securities were $15.3 billion, and the company repurchased $723 million of stock during the quarter with $2.3 billion remaining under its authorization.

Aug 3, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Bylaw Amendment (Jun 14, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 13, 2023, detailing key corporate governance actions and shareholder vote outcomes from its Annual Meeting held on June 9, 2023. The most significant governance change involves an amendment to the company's By-Laws to implement its previously disclosed Board leadership succession plan, allowing for the election of two Co-Chairs of the Board. Shareholders overwhelmingly approved routine matters, including the election of Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023, and the advisory vote on executive compensation. The company will continue with annual advisory votes on executive compensation. A shareholder proposal related to access to medicine in intellectual property protection was not approved.

Jun 14, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (May 4, 2023)

Regeneron's first quarter 2023 results showed total revenues up 7% year over year to $3.16 billion, driven primarily by Sanofi collaboration revenue (up 26% to $798 million) on higher Dupixent profit share, partly offset by a 6% decline in U.S. EYLEA net sales to $1.43 billion as higher sales-related deductions outweighed volume gains. GAAP diluted EPS fell 17% to $7.17 from $8.61, while non-GAAP diluted EPS declined 12% to $10.09, with both figures absorbing a $0.42 charge from acquired IPR&D, including a $45 million up-front payment to Sonoma Biotherapeutics. Operating expenses rose sharply, with GAAP R&D up 30% and SG&A up 34%, reflecting higher headcount and the assumption of worldwide Libtayo commercialization responsibilities. Management raised its 2023 GAAP R&D and SG&A guidance and lowered GAAP gross margin and tax rate guidance, while leaving non-GAAP R&D and SG&A unchanged. Cash and marketable securities reached $15.0 billion, and the company repurchased $694 million of stock in the quarter, with $3.05 billion remaining under its authorizations. Free cash flow fell to $1.19 billion from $1.96 billion a year earlier, as operating cash flow dropped to $1.37 billion from $2.10 billion. Pipeline news was mixed but notable. The Dupixent COPD Phase 3 trial met its primary and key secondary endpoints, with a 30% reduction in moderate or severe exacerbations, and the aflibercept 8 mg BLA is under FDA priority review with a June 27, 2023 target action date. A Dupixent chronic cold induced urticaria study failed and was discontinued. The company also announced that Chair P. Roy Vagelos will retire at the June 2023 annual meeting, after which Leonard Schleifer and George Yancopoulos are planned to become co-chairs.

May 4, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Apr 17, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant leadership transition in its upcoming 2023 Annual Meeting of Shareholders. Dr. P. Roy Vagelos, the current Chair of the Board, has decided not to stand for re-election. This marks the end of his tenure, during which he will continue to serve until the conclusion of the meeting on June 9, 2023. The company has stated that Dr. Vagelos's decision was not due to any disagreements regarding the company's operations or policies.

Apr 17, 2023 8-K

Material AgreementsFinancial EventsExhibits & Filings

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 10, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 10, 2023, to disclose an expected acquired in-process research and development (IPR&D) charge for the first quarter of 2023. This charge is primarily related to an upfront payment for their collaboration and license agreement with Sonoma Biotherapeutics, Inc. The company anticipates a pre-tax IPR&D charge of approximately $56 million, which is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $0.42 for the quarter. While this charge is a notable event impacting short-term profitability per share, investors should note that such IPR&D charges are inherently unpredictable and are not typically forecasted by the company. The disclosed figures are preliminary estimates and are subject to finalization of the company's financial closing procedures. Investors should monitor future filings for finalized financial results and strategic updates regarding the Sonoma Biotherapeutics collaboration.

Apr 10, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Material Agreement (Mar 29, 2023)

On March 27, 2023, Regeneron Pharmaceuticals and certain subsidiaries entered into amended and restated agreements governing the $720.0 million lease financing for its corporate headquarters and approximately 150-acre campus in Mount Pleasant and Greenburgh, New York. The Third Amended and Restated Participation Agreement, Lease and Remedies Agreement, and Guaranty replace the Second A&R versions from March 2022. The changes are primarily structural and aligning terms: covenants, representations, warranties, and events of default were revised to be substantially similar to those in Regeneron's December 19, 2022 Credit Agreement with JPMorgan Chase Bank, N.A. Key economic terms remain unchanged. The maturity date of March 3, 2027 is retained, as is the yield structure, which is based on one-month forward-looking SOFR plus a spread adjustment and an applicable margin tied to Regeneron's debt rating and leverage ratio. The lease remains triple-net, so Regeneron bears maintenance, insurance, taxes, and other facility costs, partly offset by sublease income from third-party tenants. Regeneron continues to guarantee all lessee obligations. Subsidiary guarantors become jointly and severally liable only when they have an outstanding borrowing under the Credit Agreement, and none currently does. For investors, the filing signals no new capital raised and no change to the financing's cost or maturity. It does show that Regeneron has harmonized its real estate financing covenants with its more recent revolving credit facility, which reduces the number of differing covenant packages across its debt. The company retains options to extend the term for five years with participant consent, to purchase the facility, or to sell it on the lessor's behalf, and the obligations can be prepaid without premium, subject to customary breakage costs.

Mar 29, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Feb 3, 2023)

Regeneron reported fourth-quarter 2022 revenue of $3.41 billion, down 31% from the prior year, and full-year 2022 revenue of $12.17 billion, down 24%. The declines reflect the absence of U.S. REGEN-COV sales, which were $2.30 billion in Q4 2021 and zero in 2022. Excluding REGEN-COV and Ronapreve, revenue rose 14% in the quarter and 17% for the year. Full-year GAAP diluted EPS was $38.22, down 47%, and non-GAAP diluted EPS was $44.98, down 40%. Q4 GAAP diluted EPS of $10.50 included a $0.21 unfavorable impact from an acquired IPR&D charge. Core franchises showed mixed momentum. Dupixent global net sales (recorded by Sanofi) grew 40% for the year to $8.68 billion, and Regeneron's share of antibody commercialization profits drove Sanofi collaboration revenue up 50%. U.S. EYLEA net sales rose 8% for the year to $6.26 billion, but fell 3% in Q4 because of a shift to compounded bevacizumab, a temporary closure of a co-pay assistance fund, and higher sales deductions. Libtayo gained first-line NSCLC approval in combination with chemotherapy, and Regeneron assumed worldwide commercialization rights effective July 1, 2022. The key forward catalysts are the aflibercept 8 mg BLA for wet AMD and DME, which carries a priority review voucher and a potential FDA decision in Q3 2023, and the EYLEA ROP sBLA with a February 11, 2023 target action date. Management guided 2023 non-GAAP R&D to $3.725–$3.925 billion, non-GAAP SG&A to $2.130–$2.280 billion, and capital expenditures to $825–$950 million. The board authorized a new $3.0 billion share repurchase program in January 2023, following $2.1 billion of repurchases in 2022. Cash and marketable securities stood at $14.33 billion at year-end. Full-year free cash flow fell to $4.42 billion from $6.53 billion.

Feb 3, 2023 8-K

Material AgreementsFinancial EventsExhibits & Filings

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 9, 2023)

Regeneron (REGN) used its presentation at the 41st J.P. Morgan Healthcare Conference on January 9, 2023 to provide a preliminary, unaudited look at its fourth quarter and full-year 2022 results. U.S. net product sales of EYLEA (aflibercept) were approximately $6.26 billion for full-year 2022, up about 8% year over year, while fourth-quarter 2022 U.S. EYLEA sales were roughly $1.50 billion, down about 3% year over year. Management attributed the soft quarter to a short-term shift to off-label compounded Avastin (bevacizumab) and the temporary closing of a patient co-pay assistance fund in Q4, and said Q4 market data suggested the Avastin shift was already beginning to reverse. EYLEA held about 75% branded anti-VEGF category share in December 2022. The company also disclosed an expected acquired in-process R&D charge of about $30 million tied to an up-front payment under its CytomX Therapeutics collaboration. This is expected to reduce both GAAP and non-GAAP diluted EPS for Q4 2022 by about $0.21. Management emphasized that the figures remain unaudited and subject to closing procedures, so final results could differ. Beyond the numbers, the presentation outlined a 2023 catalyst path centered on aflibercept 8 mg, which has a BLA submitted with a priority review voucher and a potential FDA decision and U.S. launch by late August 2023, alongside Dupixent label expansions and pipeline readouts in oncology and COPD. Investors will likely focus on whether EYLEA's share and volume recover in 2023 and whether aflibercept 8 mg can extend the franchise's leadership against competitors such as faricimab.

Jan 9, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Material Agreement (Dec 20, 2022)

Regeneron Pharmaceuticals, Inc. (REGN) has entered into a new $750 million senior unsecured five-year revolving credit facility, replacing its previous facility of the same size. This new credit agreement, effective December 19, 2022, provides Regeneron with financial flexibility for working capital needs and general corporate purposes. The facility features a variable interest rate tied to SOFR or alternate base rate, plus an applicable margin that adjusts based on the company's debt rating and leverage ratio. Notably, the agreement includes an option for Regeneron to incorporate environmental, social, and governance (ESG) targets to potentially adjust pricing, aligning with increasing investor focus on sustainability metrics.

Dec 20, 2022 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Nov 3, 2022)

Regeneron reported third quarter 2022 results with total revenues down 15% year-over-year to $2.94 billion, though revenues excluding REGEN-COV and Ronapreve grew 11% to $2.93 billion. The decline reflects the absence of U.S. REGEN-COV sales in 2022, which had contributed $677 million in Q3 2021. Core franchises performed well: U.S. EYLEA net sales rose 11% to a record $1.63 billion, and global Dupixent sales (recorded by Sanofi) increased 40% to $2.33 billion. GAAP diluted EPS was $11.66 versus $14.33 a year earlier, while non-GAAP diluted EPS was $11.14, down 28%, with the GAAP figure boosted by $254 million of unrealized gains on equity securities. Pipeline news was the main positive catalyst. Phase 3 PHOTON (DME) and PULSAR (wet AMD) trials met primary endpoints for aflibercept 8 mg, with 12- and 16-week dosing achieving non-inferiority to EYLEA's 8-week regimen. The company plans a BLA submission in late 2022 using a priority review voucher. EYLEA also received six months of pediatric exclusivity, extending U.S. market exclusivity through May 17, 2024. Regeneron discontinued fasinumab development and the Phase 3 cat allergy study (REGN1908-1909) due to futility. Following the worldwide Libtayo rights acquisition from Sanofi effective July 1, 2022 (a $900 million upfront payment), the company now records Libtayo sales outside the U.S. directly. Full-year 2022 guidance was mostly maintained or refined, with R&D guidance raised on a GAAP basis to $3.515-$3.600 billion and other operating income expected at approximately $85 million. Capital allocation remained active: the company repurchased $913 million of stock in the quarter and had $1.186 billion remaining under its authorization, and it allocated over $2.8 billion to buybacks and business development in the first nine months of 2022. Investors should weigh the strong core franchise growth and pipeline progress against the revenue decline from the REGEN-COV roll-off and rising R&D and SG&A spending.

Nov 3, 2022 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Oct 3, 2022)

Regeneron Pharmaceuticals, Inc. (REGN) announced an important change to its Board of Directors through an 8-K filing on October 3, 2022. The company has elected Craig B. Thompson, M.D. as a new director, expanding the Board from 12 to 13 members. Dr. Thompson's appointment is effective immediately and he will serve until the 2023 Annual Shareholder Meeting. This addition signifies a potential strengthening of the Board's expertise, particularly in technology, as Dr. Thompson has also been appointed to the Board's Technology Committee. Investors should note that Dr. Thompson's compensation will align with the company's existing non-employee director compensation structure, as previously detailed in their proxy statement. There are no disclosed understandings or arrangements with other parties regarding his selection. This move is a governance update that could impact strategic oversight and technological direction for Regeneron.

Oct 3, 2022 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Aug 3, 2022)

Regeneron reported second quarter 2022 results on August 3, 2022. Total revenues fell 44% to $2.857 billion from $5.139 billion a year earlier, largely because U.S. REGEN-COV sales ended (there were none in 2022 after final government deliveries in 2021). Excluding REGEN-COV and Ronapreve, revenues grew 20% to $2.849 billion. The core business showed strength: U.S. EYLEA net sales rose 14% to a record $1.62 billion, and Sanofi-recorded Dupixent global sales rose 40% to $2.09 billion. GAAP diluted EPS was $7.47 versus $27.97 a year ago, while non-GAAP diluted EPS was $9.77, which absorbed a $1.71 per-share hit from acquired IPR&D, including a $195 million charge tied to the Checkmate Pharmaceuticals acquisition. Year-over-year GAAP comparisons are also distorted by a $164 million unrealized loss on equity securities versus a $409 million gain in Q2 2021. Management raised its 2022 GAAP R&D, SG&A and gross margin guidance to reflect the July 1, 2022 acquisition of worldwide Libtayo rights from Sanofi, which carried a $900 million upfront payment, and the completed Checkmate acquisition. Guidance for COCM and the ETR was lowered. Cash and marketable securities rose to $13.98 billion, and free cash flow for the first half was $2.37 billion. Investors should note that the company is shifting its oncology exposure and that the 2022 guidance excludes any significant business development deals not completed by the release date. Near-term catalysts include a September 30, 2022 PDUFA date for Dupixent in prurigo nodularis, a February 28, 2023 target date for EYLEA every-16-weeks dosing in diabetic retinopathy, and oncology and ophthalmology clinical readouts expected in the second half of 2022.

Aug 3, 2022 8-K

Regeneron Pharmaceuticals 8-K Report, Shareholder Vote Results (Jun 15, 2022)

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 15, 2022, detailing the outcomes of its 2022 Annual Meeting of Shareholders held on June 10, 2022. The primary focus of this report is the voting results on key corporate governance and financial matters. Investors will be interested to note that all proposed items were overwhelmingly approved by shareholders, indicating strong support for the company's management and strategic direction. Specifically, the election of Class I directors received substantial support, with all nominees elected to serve until the 2025 Annual Meeting. Furthermore, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year 2022, a crucial vote of confidence in the company's financial oversight. Finally, an advisory vote on executive compensation was also approved, suggesting shareholder satisfaction with the remuneration of the company's named executive officers.

Jun 15, 2022 8-K

Material Agreements

Regeneron Pharmaceuticals 8-K Report, Material Agreement (Jun 2, 2022)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing a significant amendment to its Immuno-Oncology License and Collaboration Agreement (IO LCA) with Sanofi Biotechnology, effective upon the A&R Effective Date. This amendment fundamentally restructures the parties' collaboration, granting Regeneron sole worldwide rights to develop and commercialize Libtayo® (cemiplimab). This shift represents a major strategic move for Regeneron, consolidating control over a key asset and streamlining its commercialization efforts. The financial implications of this agreement are substantial. Regeneron will make a $900 million upfront payment to Sanofi, along with potential milestone payments. Post-amendment, Regeneron will retain all Libtayo profits, paying Sanofi an 11% royalty on net product sales through March 2034, and also reimbursing Sanofi for certain development costs through a royalty mechanism. Additionally, an amendment to the Antibody LCA increases Regeneron's share of profits used for development cost reimbursement. Investors should monitor the impact of these payments and the transition of commercial responsibilities on Regeneron's near-term financial performance and its long-term profitability of Libtayo.

Jun 2, 2022 8-K

Material AgreementsFinancial EventsExhibits & Filings

Regeneron Pharmaceuticals 8-K Report, Financial Results (May 4, 2022)

Regeneron (REGN) reported first quarter 2022 results on May 4, 2022, with total revenues up 17% year over year to $2.965 billion (up 25% excluding REGEN-COV and Ronapreve revenues). The growth was driven primarily by Dupixent, whose global net sales recorded by Sanofi rose 43% to $1.81 billion, and by EYLEA U.S. net sales, which rose 13% to $1.52 billion. Collaboration revenue reached $1.233 billion, led by higher Sanofi profit shares from antibody commercialization ($415 million) and a $216 million Roche payment tied to Ronapreve. GAAP diluted EPS was $8.61, down 15% from $10.09, mainly because of a $211 million net unrealized loss on equity securities. Non-GAAP diluted EPS rose 16% to $11.49. Net product sales in the U.S. fell 5%, reflecting the absence of REGEN-COV sales, which were $262 million in the prior-year quarter. Operating cash flow was $2.1 billion and free cash flow was $1.96 billion, aided by collection of amounts due from the U.S. government for REGEN-COV sales in the fourth quarter of 2021. The company repurchased $352 million of stock in the quarter and had $2.493 billion remaining under its buyback authorization. Full-year 2022 guidance was raised on R&D, with non-GAAP R&D now $2.9 to $3.1 billion, and non-GAAP ETR was lowered to 12% to 14%. Non-GAAP R&D was reduced by $100 million at the low and high ends, and GAAP R&D was raised by $100 million at both ends. Key catalysts ahead include FDA priority review decisions for Dupixent in children with atopic dermatitis (target date June 9, 2022) and in adults and adolescents with eosinophilic esophagitis (target date August 3, 2022). The REGEN-COV BLA review was extended to a July 13, 2022 target date after a Major Amendment for pre-exposure prophylaxis. The pending Checkmate Pharmaceuticals acquisition, valued at about $250 million, is expected to close in mid-2022. Investors should note REGEN-COV's sharp revenue decline after the FDA's January 2022 EUA revision, which excluded use against Omicron-lineage variants, and the $58 million of related COGS charges.

May 4, 2022 8-K

Regeneron Pharmaceuticals 8-K Report, Material Agreement (Mar 8, 2022)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing material definitive agreements related to its corporate headquarters and laboratory space. The company, through its subsidiary Old Saw Mill Holdings LLC, has extended a $720.0 million lease financing agreement for its New York-based facilities. This extension spans five years, moving the maturity date from March 2022 to March 2027. The amended agreements involve a restated participation agreement and a restated lease, which govern the financing and the company's use of the property. These extensions provide continued operational stability and maintain the existing financing structure for these critical assets. The terms include variable interest rates based on SOFR plus a spread and margin, and Regeneron continues to operate under a triple-net lease structure for the facility. The company retains options for further extension or a potential purchase of the facility at maturity.

Mar 8, 2022 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Feb 4, 2022)

Regeneron reported strong fourth quarter and full year 2021 results, with total revenues rising 104% to $4.95 billion in Q4 and 89% to $16.07 billion for the year. A large share of that growth came from REGEN-COV, the COVID-19 antibody cocktail, which contributed $2.30 billion in Q4 and $6.19 billion for the full year. Excluding REGEN-COV and the Roche true-up payment, revenues grew 17% in Q4 and 19% for the year to $9.88 billion, which better reflects the core franchise. GAAP diluted EPS was $19.69 for Q4 and $71.97 for the full year, while non-GAAP diluted EPS was $23.72 and $74.66, respectively. Core products performed well. EYLEA U.S. net sales rose 15% in Q4 to $1.55 billion, and Dupixent global net sales, recorded by Sanofi, rose 51% to $1.77 billion. Full-year 2021 free cash flow was $6.53 billion, helped by collections from the U.S. government on REGEN-COV sales, and the board authorized a new $3.0 billion share repurchase program. Q4 profitability was dented by a $232 million REGEN-COV inventory write-down after Omicron data and the FDA's revised EUA, which left the product with no authorized U.S. use. Looking ahead, the company guided 2022 non-GAAP R&D to $2.80–$3.00 billion and non-GAAP SG&A to $1.65–$1.77 billion. Key 2022 catalysts include the EYLEA 8 mg Phase 3 readouts, the April 13, 2022 FDA action date for the COVID-19 BLA, and the September 19, 2022 Libtayo NSCLC action date. Investors will also watch the next-generation antibodies being developed against Omicron and other variants, since REGEN-COV's COVID-19 revenue is unlikely to recur at 2021 levels.

Feb 4, 2022 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 10, 2022)

Regeneron Pharmaceuticals (REGN) furnished an 8-K on January 10, 2022, in connection with its presentation at the virtual 40th Annual J.P. Morgan Healthcare Conference. The filing discloses preliminary, unaudited U.S. net product sales for full-year 2021 of approximately $5.79 billion for EYLEA (aflibercept) and approximately $5.82 billion for REGEN-COV (casirivimab and imdevimab), with fourth-quarter 2021 figures of roughly $1.54 billion and $2.29 billion, respectively. The company characterized EYLEA as the number one prescribed FDA-approved anti-VEGF treatment for retinal disease with roughly 75% share of the U.S. branded category, and reported 4Q21 EYLEA sales up 15% year over year and full-year sales up 17%. Beyond the commercial metrics, the presentation laid out a broad development agenda: positive Phase 3 results across four potential new Dupixent indications (chronic spontaneous urticaria, prurigo nodularis, eosinophilic esophagitis, and pediatric atopic dermatitis), a $1.8 billion investment in R&D and manufacturing capacity, and a $3 billion share repurchase authorization announced in November 2021 on top of more than $7.5 billion repurchased since November 2019. Management also highlighted a pipeline of more than 30 therapeutic candidates, a 2H22 Phase 3 readout for aflibercept 8mg, and an upcoming FDA decision (PDUFA date April 13, 2022) on the REGEN-COV BLA for treatment and prophylaxis. For investors, the key takeaways are the strong EYLEA franchise and the rapid expansion of the Dupixent opportunity, alongside a COVID-19 antibody revenue stream that is material in 2021 but inherently subject to pandemic-driven demand, government procurement, and variant risk. The figures are preliminary and unaudited, and the presentation uses a non-GAAP measure (total revenues excluding REGEN-COV). The 8-K states that the information is furnished rather than filed under the Exchange Act.

Jan 10, 2022 8-K